Pfizer's maternal RSV vaccine approved to help protect newborns
Pfizer’s RSV vaccine is now approved to help protect newborns when administered to women between 32 and 36 weeks of pregnancy.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
